3.50
price down icon0.85%   -0.03
 
loading
Schlusskurs vom Vortag:
$3.53
Offen:
$3.52
24-Stunden-Volumen:
136.01K
Relative Volume:
0.33
Marktkapitalisierung:
$35.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1779
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
-2.23%
1M Leistung:
+25.00%
6M Leistung:
+15.13%
1J Leistung:
-17.45%
1-Tages-Spanne:
Value
$3.42
$3.58
1-Wochen-Bereich:
Value
$3.42
$3.74
52-Wochen-Spanne:
Value
$2.30
$4.42

Polypid Ltd Stock (PYPD) Company Profile

Name
Firmenname
Polypid Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
61
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-13
Name
Neueste SEC-Einreichungen
Name
PYPD's Discussions on Twitter

Vergleichen Sie PYPD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PYPD
Polypid Ltd
3.50 35.67M 0 -23.87M -47.63M -19.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
539.49 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.02 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
549.56 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.36 28.51B 3.81B -644.79M -669.77M -6.24

Polypid Ltd Stock (PYPD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-05 Eingeleitet Roth Capital Buy
2025-06-02 Fortgesetzt H.C. Wainwright Buy
2025-01-28 Eingeleitet Rodman & Renshaw Buy
2021-09-14 Eingeleitet JMP Securities Mkt Outperform
2021-07-30 Eingeleitet Cantor Fitzgerald Overweight
2020-11-24 Hochstufung Raymond James Outperform → Strong Buy
2020-08-10 Eingeleitet Alliance Global Partners Buy
2020-07-21 Eingeleitet BMO Capital Markets Outperform
2020-07-21 Eingeleitet Barclays Overweight
2020-07-21 Eingeleitet Raymond James Outperform
Alle ansehen

Polypid Ltd Aktie (PYPD) Neueste Nachrichten

pulisher
Jun 18, 2025

Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Roth Capital Adjusts PolyPid (PYPD) Price Target Amid New Financing | PYPD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

PolyPid (NASDAQ:PYPD) Given New $14.00 Price Target at JMP Securities - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

PYPD: JMP Securities Lowers Price Target While Maintaining Marke - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid (PYPD) Price Target Adjusted Amid Financing Developments - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid stock price target lowered to $14 at JMP on warrant dilution By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid stock price target lowered to $14 at JMP on warrant dilution - Investing.com Australia

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Citizens JMP Adjusts Price Target for PolyPid (PYPD) Amid Warrant Developments | PYPD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

FY2026 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World

Jun 13, 2025
pulisher
Jun 11, 2025

PESG Research Update: PolyPid SHIELD’s II Delivers - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline ResultsParadigm Shift in Surgical Infection Prevention - Yahoo

Jun 11, 2025
pulisher
Jun 11, 2025

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed - insights.citeline.com

Jun 11, 2025
pulisher
Jun 10, 2025

HC Wainwright Issues Positive Forecast for PolyPid (NASDAQ:PYPD) Stock Price - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

PolyPid reports positive phase 3 surgical infection drug trial - גלובס

Jun 10, 2025
pulisher
Jun 09, 2025

PolyPid (PYPD) Target Price Increased as Phase 3 Trial Data Impr - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid shares surge on successful D-PLEX100 trial results By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid shares surge on successful D-PLEX100 trial results - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : PolyPid Ltd.Special Call - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid (PYPD) Reports Positive Phase 3 Trial Results for D-PLEX100 | PYPD Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

What is Roth Capital’s Forecast for PolyPid Q2 Earnings? - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Roth Capital Begins Coverage on PolyPid (NASDAQ:PYPD) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

PolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100 - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

PolyPid to Host Conference Call and Webcast to Discuss - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Major Clinical Trial Results: PolyPid's D-PLEX100 Shows New Data for Preventing Post-Surgery Infections - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rat - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rating | PYPD Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates PolyPid at Buy With $9 Price Target - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

PolyPid initiated with a Buy at Roth Capital - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

What is HC Wainwright’s Forecast for PolyPid Q2 Earnings? - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

FY2027 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

PolyPid (NASDAQ:PYPD) Upgraded by HC Wainwright to “Buy” Rating - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

PolyPid (NASDAQ:PYPD) Now Covered by HC Wainwright - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Wall Street Analyst Says PolyPid is a Buy with 300% Potential Upside as it nears Phase 3 Data Readout - newsblaze.com

Jun 02, 2025
pulisher
Jun 02, 2025

PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Through Clinical Trials to Improve Surgical Outcomes, Enhance Treatment Efficacy, Minimize Side Effects - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright assumes coverage on PolyPid stock with buy rating - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

PolyPid assumed with a Buy at H.C. Wainwright - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright assumes coverage on PolyPid stock with buy rating By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

PolyPid (PYPD) Receives a 'Buy' Rating from HC Wainwright & Co. - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright Initiates Buy Coverage on PolyPid (PYPD) with $1 - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - Defense World

May 31, 2025
pulisher
May 30, 2025

PolyPid Expands Share Option Plan to Boost Stakeholder Engagement - TipRanks

May 30, 2025

Finanzdaten der Polypid Ltd-Aktie (PYPD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.80
price up icon 0.70%
$35.82
price down icon 0.53%
$21.32
price up icon 0.09%
$97.77
price down icon 2.79%
$108.15
price up icon 1.58%
biotechnology ONC
$244.00
price up icon 0.85%
Kapitalisierung:     |  Volumen (24h):